期刊文献+

胃癌的免疫治疗 被引量:2

Immunotherapy of gastric cancer
下载PDF
导出
摘要 胃癌的死亡率较高,在肿瘤相关死亡率上排名第二,在我国大部分诊断为进展期胃癌。近年来,肿瘤治疗趋向于综合治疗,主要手段是手术、放疗和化疗。免疫治疗是一种有前景的新兴的临床治疗癌症的方法,已经在黑色素瘤、乳腺癌和前列腺癌中取得很大的成功。现对现代肿瘤免疫治疗概念、目前的方法和在胃癌免疫治疗中的前景进行综述。 Gastric cancer has a higher mortality rate, which is the second most common of malignancies in the world.When came to clinical medicine most patients already belongs to advanced gastric cancer in China. Recently, cancer treatment tends to comprehensive treatment, the three main methods are surgical treatments, radiotherapy and chemotherapy. Cancer immunotherapy is a promising approach for clinical treatment of cancer. It has shown some success in melanoma, breast cancer and prostate cancer. This paper summarizes the concept of modern cancer immunity,approach, and immune therapy in the treatment of gastric cancer in the future prospect.
作者 尹竺晟 戈伟
出处 《中国医药导报》 CAS 2015年第29期35-38,共4页 China Medical Herald
关键词 胃癌 免疫逃逸 过继细胞免疫治疗 肿瘤疫苗 单克隆抗体 Gastric cancer Immune escape Adoptive immunotherapy Tumor vaccine Monoclonal antibody therapy
  • 相关文献

参考文献7

二级参考文献121

共引文献145

同被引文献65

  • 1Ji Yeong An,Yoo Min Kim,Min Ah Yun,Byeong Hee Jeon,Sung Hoon Noh.Improvement of type 2 diabetes mellitus after gastric cancer surgery:Short-term outcome analysis after gastrectomy[J].World Journal of Gastroenterology,2013,19(48):9410-9417. 被引量:13
  • 2Ryouichi Tomita, Kenichi Sakurai, Shigeru Fujisaki. Sig- nificance of the Lower Esophageal Sphincter Preservation in Preventing Alkaline Reflux Esophagitis in Patients After Total Gastrectomy Reconstructed by Roux-en-Y for Gastric Cancer [J]. Int Surg,2014,99(2) :174-181.
  • 3Ikuyo Imayama,Catherine M Alfano, Marian L Neuhous- er,et al. Weight,inflammation,cancer-related symptoms and health-related quality of life among breast cancer survivors [J]. Published in final edited form as:Breast Cancer Res Treat,2013,140(1) : 159-176.
  • 4Laura P Forsythe, Catherine M Alfano, Erin E Kent, et al. Social Support, Self -Efficacy for Decision Making, and Follow-up Care Use in Long-term Cancer Survivors [J].Published in final edited form as: Psychooncology,2014, 23(7) :788-796.
  • 5Bernstein WB, Dennis PA. Repositioning HIV protease in- hibitors as cancer therapeutics [J]. Current Opinion HIV & AIDS,2008,3(6) :666 - 675.
  • 6Chow WA,Jiang C,Guan M. Anti-HIV drugs for cancer therapeutics:back to the future? [J]. Lancet Oncology,2009, 10(1) :61-71.
  • 7AK Gupta, Cerniglia GJ, Rosemarie GJ, et al. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo [J]. Cancer Research,2005, 65 (18) : 8256-8265.
  • 8Gills J J, Lopiccolo J,Tsurutani J, et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum,anticancer a- gent that induces endoplasmic reticulum stress,au- tophagy,and apoptosis in vitro and in vivo [J]. Clinical Cancer Research, 2007,13 (17) : 5183-5194.
  • 9Gills J J, Lopiccolo J, Dennis PA. Nelfinavir,a new anti- cancer drug with pleiotropic effects and many paths to au- tophagy [J]. Autophagy, 2008,4 ( 1 ) : 107-109.
  • 10Lucia MB,Anu R,Handley M,et al. Exposure to HIV- protease inhibitors selects for increased expression of P- glycoprotein (ABCB1) in Kaposi's sarcoma cells [J]. British Journal of Cancer, 2011,105 (4) : 513-522.

引证文献2

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部